Syngene International Limited is one of the leading India-based contract research organizations (CRO), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across various industrial sectors, including pharmaceuticals, biotechnology, agrochemicals, consumer health, animal health, cosmetics, and nutrition companies. Its service offerings in discovery and development span multiple domains, including small molecules, large molecules, antibody-drug conjugates (ADC), and oligonucleotides.
The company's integrated discovery and development platforms help organizations conduct discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluations, formulation development, and stability studies), and pilot manufacturing (scale-up, pre-clinical, and clinical supplies) under one roof, providing a distinctive economic advantage. The company's services also support the development of biosimilar and generic molecules. In
Syngene International Limited is one of the leading India-based contract research organizations (CRO), offering a suite of integrated, end-to-end discovery and development services for novel molecular entities (NMEs) across various industrial sectors, including pharmaceuticals, biotechnology, agrochemicals, consumer health, animal health, cosmetics, and nutrition companies. Its service offerings in discovery and development span multiple domains, including small molecules, large molecules, antibody-drug conjugates (ADC), and oligonucleotides.
The company's integrated discovery and development platforms help organizations conduct discovery (from hit to candidate selection), development (including pre-clinical and clinical studies, analytical and bio-analytical evaluations, formulation development, and stability studies), and pilot manufacturing (scale-up, pre-clinical, and clinical supplies) under one roof, providing a distinctive economic advantage. The company's services also support the development of biosimilar and generic molecules. In the near term, the company plans to forward integrate into commercial-scale manufacturing of NMEs.
Outsourcing discovery and development work has become an established alternative to in-house development among multinational organizations. While multinational companies traditionally used outsourcing as a means to reduce their research and development (R&D) expenditures, the R&D outsourcing industry is evolving from simply leveraging cost arbitrage to enhancing R&D productivity and reducing the time to market
Show More